FTC About to Let Through a ‘Killer Acquisition’

In this Capitol Forum report, the merger of Roche and Spark Therapeutics, which could squash a cure for hemophilia while allowing Roche’s medication for it to thrive, is poised to be approved.

by

The American Prospect is nonprofit, reader-funded journalism—and we need your help.

Our reporters dig deep, hold power to account, and explain how policy shapes people’s lives. If you value independent journalism that goes beyond the headlines, now’s the time to support it.

Here’s how you can help:
Donate to power fearless reporting
Subscribe to get our print magazine 6x/year. 

Every dollar funds our in-depth reporting. 


Donate Now. Subscribe here.